These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16403771)

  • 1. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.
    Choudhry NK; Anderson GM; Laupacis A; Ross-Degnan D; Normand SL; Soumerai SB
    BMJ; 2006 Jan; 332(7534):141-5. PubMed ID: 16403771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Warfarin at Discharge Among Acute Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation in China.
    Yang X; Li Z; Zhao X; Wang C; Liu L; Wang C; Pan Y; Li H; Wang D; Hart RG; Wang Y; Wang Y;
    Stroke; 2016 Feb; 47(2):464-70. PubMed ID: 26696643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
    Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE
    JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics.
    Choudhry NK; Soumerai SB; Normand SL; Ross-Degnan D; Laupacis A; Anderson GM
    Am J Med; 2006 Jul; 119(7):607-15. PubMed ID: 16828633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation?
    Beyth RJ; Antani MR; Covinsky KE; Miller DG; Chren MM; Quinn LM; Landefeld CS
    J Gen Intern Med; 1996 Dec; 11(12):721-8. PubMed ID: 9016418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin.
    Schauer DP; Moomaw CJ; Wess M; Webb T; Eckman MH
    J Gen Intern Med; 2005 Dec; 20(12):1114-9. PubMed ID: 16423100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
    Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
    Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
    Di Biase L; Burkhardt JD; Santangeli P; Mohanty P; Sanchez JE; Horton R; Gallinghouse GJ; Themistoclakis S; Rossillo A; Lakkireddy D; Reddy M; Hao S; Hongo R; Beheiry S; Zagrodzky J; Rong B; Mohanty S; Elayi CS; Forleo G; Pelargonio G; Narducci ML; Dello Russo A; Casella M; Fassini G; Tondo C; Schweikert RA; Natale A
    Circulation; 2014 Jun; 129(25):2638-44. PubMed ID: 24744272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation.
    Boulanger L; Hauch O; Friedman M; Foster T; Dixon D; Wygant G; Menzin J
    Ann Pharmacother; 2006 Jun; 40(6):1024-9. PubMed ID: 16735649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.
    Carrero JJ; Evans M; Szummer K; Spaak J; Lindhagen L; Edfors R; Stenvinkel P; Jacobson SH; Jernberg T
    JAMA; 2014 Mar; 311(9):919-28. PubMed ID: 24595776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital.
    Yousef ZR; Tandy SC; Tudor V; Jishi F; Trent RJ; Watson DK; Cowell RP
    Heart; 2004 Nov; 90(11):1259-62. PubMed ID: 15486116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.